Cargando…

Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics

Substance abuse is a fundamentally dynamic disease, characterized by repeated oscillation between craving, drug self-administration, reward, and satiety. To model nicotine addiction as a control system, a magnetic resonance imaging (MRI)-compatible nicotine delivery system is needed to elicit cyclic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Rajat, Mujica-Parodi, Lilianne R., Wenke, Michael, Amgalan, Anar, Lithen, Andrew, Govindarajan, Sindhuja T., Makaryus, Rany, Benveniste, Helene, Strey, Helmut H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708378/
https://www.ncbi.nlm.nih.gov/pubmed/34959350
http://dx.doi.org/10.3390/pharmaceutics13122069
_version_ 1784622669901070336
author Kumar, Rajat
Mujica-Parodi, Lilianne R.
Wenke, Michael
Amgalan, Anar
Lithen, Andrew
Govindarajan, Sindhuja T.
Makaryus, Rany
Benveniste, Helene
Strey, Helmut H.
author_facet Kumar, Rajat
Mujica-Parodi, Lilianne R.
Wenke, Michael
Amgalan, Anar
Lithen, Andrew
Govindarajan, Sindhuja T.
Makaryus, Rany
Benveniste, Helene
Strey, Helmut H.
author_sort Kumar, Rajat
collection PubMed
description Substance abuse is a fundamentally dynamic disease, characterized by repeated oscillation between craving, drug self-administration, reward, and satiety. To model nicotine addiction as a control system, a magnetic resonance imaging (MRI)-compatible nicotine delivery system is needed to elicit cyclical cravings. Using a concentric nebulizer, inserted into one nostril, we delivered each dose equivalent to a single cigarette puff by a syringe pump. A control mechanism permits dual modes: one delivers puffs on a fixed interval programmed by researchers; with the other, subjects press a button to self-administer each nicotine dose. We tested the viability of this delivery method for studying the brain’s response to nicotine addiction in three steps. First, we established the pharmacokinetics of nicotine delivery, using a dosing scheme designed to gradually achieve saturation. Second, we lengthened the time between microdoses to elicit craving cycles, using both fixed-interval and subject-driven behavior. Finally, we demonstrate a potential application of our device by showing that a fixed-interval protocol can reliably identify neuromodulatory targets for pharmacotherapy or brain stimulation. Our MRI-compatible nasal delivery method enables the measurement of neural circuit responses to drug doses on a single-subject level, allowing the development of data-driven predictive models to quantify individual dysregulations of the reward control circuit causing addiction.
format Online
Article
Text
id pubmed-8708378
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87083782021-12-25 Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics Kumar, Rajat Mujica-Parodi, Lilianne R. Wenke, Michael Amgalan, Anar Lithen, Andrew Govindarajan, Sindhuja T. Makaryus, Rany Benveniste, Helene Strey, Helmut H. Pharmaceutics Article Substance abuse is a fundamentally dynamic disease, characterized by repeated oscillation between craving, drug self-administration, reward, and satiety. To model nicotine addiction as a control system, a magnetic resonance imaging (MRI)-compatible nicotine delivery system is needed to elicit cyclical cravings. Using a concentric nebulizer, inserted into one nostril, we delivered each dose equivalent to a single cigarette puff by a syringe pump. A control mechanism permits dual modes: one delivers puffs on a fixed interval programmed by researchers; with the other, subjects press a button to self-administer each nicotine dose. We tested the viability of this delivery method for studying the brain’s response to nicotine addiction in three steps. First, we established the pharmacokinetics of nicotine delivery, using a dosing scheme designed to gradually achieve saturation. Second, we lengthened the time between microdoses to elicit craving cycles, using both fixed-interval and subject-driven behavior. Finally, we demonstrate a potential application of our device by showing that a fixed-interval protocol can reliably identify neuromodulatory targets for pharmacotherapy or brain stimulation. Our MRI-compatible nasal delivery method enables the measurement of neural circuit responses to drug doses on a single-subject level, allowing the development of data-driven predictive models to quantify individual dysregulations of the reward control circuit causing addiction. MDPI 2021-12-03 /pmc/articles/PMC8708378/ /pubmed/34959350 http://dx.doi.org/10.3390/pharmaceutics13122069 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kumar, Rajat
Mujica-Parodi, Lilianne R.
Wenke, Michael
Amgalan, Anar
Lithen, Andrew
Govindarajan, Sindhuja T.
Makaryus, Rany
Benveniste, Helene
Strey, Helmut H.
Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics
title Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics
title_full Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics
title_fullStr Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics
title_full_unstemmed Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics
title_short Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics
title_sort development of an mri-compatible nasal drug delivery method for probing nicotine addiction dynamics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708378/
https://www.ncbi.nlm.nih.gov/pubmed/34959350
http://dx.doi.org/10.3390/pharmaceutics13122069
work_keys_str_mv AT kumarrajat developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics
AT mujicaparodililianner developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics
AT wenkemichael developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics
AT amgalananar developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics
AT lithenandrew developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics
AT govindarajansindhujat developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics
AT makaryusrany developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics
AT benvenistehelene developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics
AT streyhelmuth developmentofanmricompatiblenasaldrugdeliverymethodforprobingnicotineaddictiondynamics